New Total-Body PET scanner could revolutionize vasculitis diagnosis
NCT ID NCT07628075
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study will test a new type of PET/CT scanner, called Long-Axial Field-of-View (LAFOV), to see if it can provide clearer images of blood vessel inflammation in people with large vessel vasculitis (LVV). The scanner is more sensitive and can image the whole body faster, potentially allowing for lower radiation doses and better detection of disease activity. Researchers will compare scans from 18 participants (12 with LVV and 6 healthy volunteers) to develop a standardized imaging protocol for future use.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- 18F-FDG (a radioactive sugar) and CT contrast dye
- What this could lead to
- If successful, this could lead to a standardized, more accurate imaging protocol for diagnosing and monitoring large vessel vasculitis, potentially reducing unnecessary treatments.
- What could go wrong
- This is a very small, early-phase study (18 participants) focused on optimizing the imaging technique, not testing a treatment. The new method may not prove clearly better than current scans.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 18 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Jul 2026
An estimate. Start dates often move.
- Expected to finish
-
Jan 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria LVV Patients: * ≥18 years of age * Newly diagnosed LVV (based on the 2022 American College of Rheumatology (ACR) and European Alliance of Associations for Rheumatology (EULAR) classification criteria or from a definite diagnosis of LVV on standard of care imaging) * WHO performance status 0-2 * The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained * eGFR of ≥30 (mL/min/1.73m2) within 3 months of \[18F\]FDG injection in subjects who have a history of renal impairment, renal disease, renal transplant or diabetes Exclusion Criteria LVV Patients: * The subject is pregnant or lactating * Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure * History of allergy to iodinated contrast * Commencement of steroids \> 7 days prior to administration of the radiotracer * Poorly controlled diabetic with a blood glucose \>11mmol/L * Evidence of a significant medical condition or laboratory finding which, in the opinion of the Investigator, makes it undesirable for the patient to participate in the trial. Inclusion Criteria Healthy Volunteers: * Three subjects ≥18 years of age that are also \< 50 years old and three subjects ≥50 years of age * WHO performance status 0-2 * The subject is able and willing to comply with study procedures and signed and dated informed consent is obtained Exclusion Criteria Healthy Volunteers: * The subject is pregnant or lactating * Participants with claustrophobia or who are unable to comfortably tolerate the scanning procedure * Participants with any contra-indication to MRI * Known allergy to gadolinium-based contrast agents * History of smoking * History or current diagnosis of the following medical conditions: * Diabetes Mellitus * Chronic Kidney Disease * Atrial Fibrillation * Migraines * Rheumatoid Arthritis * Systemic Lupus Erythematosus (SLE) * Historic or current prescription of the following medications: * Any blood pressure medication * Any antipsychotic medication * Steroids * Weight of ≥75Kg (in order to keep the radiation dose \<10mSV for HV) * Evidence of any significant medical condition which, in the opinion of the Investigator, makes it undesirable for the HV to participate in the trial * Participants that have undergone any imaging investigation that exposes them to radiation within the previous 12 months
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Giant cell arteritis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
3 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Imperial College Healthcare NHS Trust
London, Greater London, W2 1NY, United Kingdom
-
King's College London
London, Greater London, SE1 7EH, United Kingdom
-
Royal Free London NHS Foundation Trust
London, Greater London, NW3 2QG, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune clues in the blood may foretell heart trouble
- Can frequent CRP checks prevent relapses in giant cell arteritis?
- Ultrasound clue vanishes days after steroids start in artery disease
- Rare artery disease linked to higher heart attack and stroke risk
- New tool could predict who will suffer from steroid side effects
- Shorter steroid course may be just as effective for giant cell arteritis